Immune Checkpoint Therapies for Melanoma

Area of Science:

• Oncology
• Immunology
• Dermatology

Background:

• Immunotherapy, specifically immune checkpoint inhibition, has revolutionized melanoma treatment.
• Approved agents include inhibitors of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1).

Purpose of the Study:

• To review the current literature on approved uses of immune checkpoint inhibition in melanoma.
• To discuss ongoing clinical trials and future directions in melanoma immunotherapy.

Main Methods:

• Literature review of approved uses of immune checkpoint inhibitors in melanoma.
• Discussion of ongoing clinical trials and novel immunotherapies.

Main Results:

• Immune checkpoint inhibitors are approved for advanced melanoma treatment (alone and in combination).
• These agents are also approved for adjuvant therapy in high-risk resected stage III melanoma.

Conclusions:

• Immune checkpoint inhibition represents a significant advancement in melanoma management.
• Ongoing research focuses on combination therapies and novel immunotherapeutic strategies for melanoma.